Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study - PubMed (original) (raw)
Randomized Controlled Trial
Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study
Ilaria Buondonno et al. PLoS One. 2017.
Abstract
The aim of this study was to evaluate differences in T helper cell sub-types and osteoclast (OCs) precursors in peripheral blood between patients affected by early rheumatoid arthritis (eRA) and healthy controls. The effect of administration of cholecalcipherol on clinical and laboratory parameters was subsequently evaluated, by a parallel, randomized double blind, placebo controlled trial. Thirty nine eRA patients and 31 age-matched controls were enrolled and compared for levels of 25OH vitamin D, T helper cell sub-types, OCs precursors including both classical and non-classical and pro-inflammatory cytokines at baseline. Eligible patients were female ≥18 years of age with a diagnosis of RA, as defined by the American College of Rheumatology 2010 criteria for <6 months prior to inclusion in the study. Patients with auto-immune or inflammatory diseases other than RA were excluded. Patients treated with glucocorticoids (GCs), disease modifying activity drugs and biologic agents within the past 6 months were also excluded. In the second phase of the study, eRA patients were randomly assigned to standard treatment with methotrexate (MTX) and GCs with (21) or without (18) cholecalcipherol (300,000 IU) and followed for 3 months; the randomization was done by computer generated tables to allocate treatments. Three patients didn't come back to the follow up visit for personal reasons. None of the patients experienced adverse events. The main outcome measures were T cells phenotypes, OCs precursors and inflammatory cytokines. Secondary outcome measure were clinical parameters. In eRA, 25OH vitamin D levels were significantly lower. CD4+/IFNγ+,CD4+/IL4+, CD4+/IL17A+ and CD4+IL17A+IFNγ+, cells were increased in eRA as well as non-classical OCs precursors, whereas T regulatory cells were not altered. TNFα, TGFβ1, RANKL, IL-23 and IL-6 were increased in eRA. Non-classical OCs, IL-23 and IL-6 correlated with disease severity and activity. Standard treatment with MTX and GC ameliorated clinical symptoms and reduced IL-23, whereas it did not affect CD4+ cells sub-sets nor OCs precursors. After 3 months, the combined use of cholecalcipherol significantly ameliorated the effect of treatment on global health. In eRA, a significant imbalance in T CD4+ sub-types accompanied by increased levels of non-classical OCs precursors and pro-inflammatory cytokines was observed. A single dose of cholecalcipherol (300,000 IU) combined with standard treatment significantly ameliorates patients general health.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Fig 1. The diagram shows the study design and the number of patients at each visit in bold, the tests performed at each visits are specified.
Fig 2. T helper subsets in eRA patients and healthy controls.
Dot plots show CD4+/IFNγ+ (panel A), CD4+/IL4+ (panel B), CD4+/IL17A+ (panel C), CD4+/IL17A+/IFNγ+ (panel D) and Tregs (panel E);mean and SD are shown, p values were calculated by Mann-Whitney test and are displayed.
Fig 3. OCs precursors in eRA patients and healthy controls.
Dot plots show classical OCs precursor (panel A), non-classical OCs precursor (panel B), RANKL (panel C) and RANKL/OPG (panel D); mean and SD are shown, p values were calculated by Mann-Whitney test and are displayed.
Fig 4. Inflammatory cytokines in eRA patients and healthy controls.
Dot plots show classical IL-23 (panel A), IL-17 (panel B), IL-4 (panel C), IL-6(panel D), TGFβ1 (panel E), TNFα (panel F) and IFNγ (panel G); mean and SD are shown, p values were calculated by Mann-Whitney test and are displayed.
Fig 5. Effect of treatment with and without cholecalcipherol on clinical parameters in eRA patients.
Graphs show DAS28 (panel A), HAQ (panel B), GH (panel C), CRP (panel D), VAS pain (panel E) and ERS (panel F); mean and SD are shown, p values were calculated by Student paired t-test and are displayed. Tables (panels G and H) show the MANOVA for repeated measures for DAS28, HAQ, GH, CRP, VAS pain and ESR and the effect of standard treatment with or without the addiction of cholecalcipherol, quadratic mean, F and p value are shown. All the analyses were done in 18 patients per group. P values were corrected for multiple comparisons.
Fig 6. Effect of treatment with and without cholecalcipherol on inflammatory cytokines in eRA patients.
Graphs show IL-23 (panel A), IL-17 (panel B), IL-6 (panel C), TNFα (panel D), TGFβ1 (panel E) and RANKL (panel F); mean and SD are shown, p values were calculated by Mann-Whitney test and are displayed. Tables (panels G and H) show the MANOVA for repeated measures for IL-23, IL-17, IL-6, TNFα, TGFβ1 and RANKL and the effect of standard treatment with or without the addition of cholecalcipherol, quadratic mean, F and p value are shown. The linear model was carried out after logarithmic transformation of non-Gaussian variables. All the analyses were done in 18 patients per group. P values were corrected for multiple comparisons.
Similar articles
- The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Kalipciyan M, Jilma B. Hobl EL, et al. Clin Exp Rheumatol. 2011 Nov-Dec;29(6):963-9. Epub 2011 Dec 22. Clin Exp Rheumatol. 2011. PMID: 22133036 Clinical Trial. - Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines.
Xinqiang S, Fei L, Nan L, Yuan L, Fang Y, Hong X, Lixin T, Juan L, Xiao Z, Yuying S, Yongzhi X. Xinqiang S, et al. Biomed Pharmacother. 2010 Sep;64(7):463-71. doi: 10.1016/j.biopha.2010.01.007. Epub 2010 Feb 25. Biomed Pharmacother. 2010. PMID: 20359858 - Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
Slauenwhite D, McAlpine SM, Hanly JG, Malik A, Haidl ID, Marshall JS, Issekutz TB. Slauenwhite D, et al. Arthritis Rheumatol. 2020 Jul;72(7):1091-1102. doi: 10.1002/art.41223. Epub 2020 May 29. Arthritis Rheumatol. 2020. PMID: 32039570 - Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J. Doyle MK, et al. Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Semin Arthritis Rheum. 2009. PMID: 18823645 Review. - Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?
Han L, Chen Z, Yu K, Yan J, Li T, Ba X, Lin W, Huang Y, Shen P, Huang Y, Qin K, Geng Y, Liu Y, Wang Y, Tu S. Han L, et al. Front Immunol. 2022 Jan 4;12:787252. doi: 10.3389/fimmu.2021.787252. eCollection 2021. Front Immunol. 2022. PMID: 35058928 Free PMC article. Review.
Cited by
- Gut Dysbiosis and Dietary Interventions in Rheumatoid Arthritis-A Narrative Review.
Bakinowska E, Stańska W, Kiełbowski K, Szwedkowicz A, Boboryko D, Pawlik A. Bakinowska E, et al. Nutrients. 2024 Sep 23;16(18):3215. doi: 10.3390/nu16183215. Nutrients. 2024. PMID: 39339815 Free PMC article. Review. - Different modalities to manage rheumatoid arthritis: an A to Z story.
Raslan MA, Raslan SA, Shehata EM, Mahmoud AS, Sabri NA, Alzahrani KJ, Alzahrani FM, Halawani IF, Azevedo V, Lundstrom K, Barh D. Raslan MA, et al. Future Sci OA. 2024 May 20;10(1):FSO968. doi: 10.2144/fsoa-2023-0134. eCollection 2024. Future Sci OA. 2024. PMID: 38827788 Free PMC article. Review. - Vitamin D and Autoimmune Rheumatic Diseases.
Athanassiou L, Kostoglou-Athanassiou I, Koutsilieris M, Shoenfeld Y. Athanassiou L, et al. Biomolecules. 2023 Apr 21;13(4):709. doi: 10.3390/biom13040709. Biomolecules. 2023. PMID: 37189455 Free PMC article. Review. - Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19.
Cutolo M, Smith V, Paolino S, Gotelli E. Cutolo M, et al. Nat Rev Rheumatol. 2023 May;19(5):265-287. doi: 10.1038/s41584-023-00944-2. Epub 2023 Mar 28. Nat Rev Rheumatol. 2023. PMID: 36977791 Free PMC article. Review. - Vitamin D and estrogen steroid hormones and their immunogenetic roles in Infectious respiratory (TB and COVID-19) diseases.
Borborema MEA, Lucena TMC, Silva JA. Borborema MEA, et al. Genet Mol Biol. 2023 Feb 6;46(1 Suppl 2):e20220158. doi: 10.1590/1415-4757-GMB-2022-0158. eCollection 2023. Genet Mol Biol. 2023. PMID: 36745756 Free PMC article.
References
- Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:745–7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous